Researchers have found a way to use nanoparticles to deliver drugs that can "wake up" the immune system and fortify its natural response to harmful cancer cells in the body.
Researchers at the National University of Singapore have developed a method for delivering the polypeptide antibiotic actinomycin D with modified, self-assembled DNA nanopyramid against bacteria such as E. coli and Staphylococcus aureus, the bug causes staph infections.
On the heels of FDA's rejection of the AcelRx New Drug Application for sublingually delivered postoperative pain killer Zalviso, CEO Richard King expounded on the "optical system errors" of the opioid drug's handheld, preprogrammed delivery device during a July 28 conference call with investors.
Mannkind endured a grueling 10-year battle for FDA approval of its inhaled insulin drug/device combination product, Afrezza. Now the dillema is how to sell it. The company needs to find a marketing partner fast.
A record-breaking material discovered last year by Swedish researchers has passed another milestone for drug delivery, showing it can hold poorly soluble drugs and, down the road, deliver them with a fast dissolution rate.
Gold nanoparticles are once again in the drug delivery spotlight as MIT scientists have discovered a mechanism by which the particles enter cells and could thus act as better drug carriers.
Alnylam announced July 22 that its intellectual property estate has been strengthened due to the U.S. Patent Office's issuance of a Notice of Allowance for claims in one of its patent applications that covers "chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target," according to a statement.
A year after the FDA rejected Titan Pharmaceutical's Probuphine subdermal implant for the treatment of opioid dependence, the company is knocking on the approval door once again. It announced July 21 that the first patients have enrolled in its Phase III trial designed to address the FDA's questions.
Galena Biopharma believes that its experienced oncology sales team will enable it to effectively market Zuplenz, the only oral soluble film for preventing vomiting following chemotherapy and radiotherapy, which it will soon offer thanks to a licensing agreement struck with MonoSol Rx, the developer of the product's delivery technology.
A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.
A biochemist has designed a method for improving the treatment of hemophilia using a plant-based drug delivery system that combats resistance to standard clotting factors, which afflicts about one-fourth of those with the disease.
Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.
Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.
Boston Scientific's Ranger drug-coated balloon catheter was recently awarded a CE mark for its 25-mm Lotus Transcatheter Aortic Valve Implantation System.
Researchers at the University of Pennsylvania said they have uncovered a delivery method to treat acute pulmonary inflammation, a condition that afflicts patients suffering from multiple blood transfusions, sepsis, lung surgery and acute lung trauma and has a mortality rate as high as 40%.
The first nasally administered naloxone-based therapy to treat emergency cases of opioid overdose from heroin or prescription painkillers received a Fast Track Designation from the FDA, product developer AntiOp said in a July 15 statement.
InSite Vision, working off its eye drop platform with polymer-suspended drug delivery, is planning to submit an NDA in 2015 for its treatment for blepharitis, an eyelid inflammation disease for which there is currently no FDA-approved treatment.
Researchers at the University of Georgia have developed a new formulation of the chemotherapy drug cisplatin that targets mitochondrial DNA, and is delivered via a polymeric nanoparticle 1,000 times smaller than the width of human hair.
Germany's CureVac will implement its RNA stabilizing RNActive technology in its new collaboration with French firm Sanofi Pasteur to develop a messenger RNA-based vaccine targeting an undisclosed pathogen.
The U.S. National Institutes of Health granted Sorrento Therapeutics $2.6 million to develop antibacterial immunotherapies.